Severe central sleep apnoea associated with nalmefene: a case report.

摘要: Nalmefene, an opioid antagonist, has recently been approved for the treatment of alcohol dependence. We describe here first case a 52-year-old woman who developed severe central sleep apnoea (CSA) 5 months after initiation nalmefene. Scoring ventilation during recording revealed apnoea-hypopnoea index 67/h with 98.7% events and 65/h. Nalmefene was withdrawn new polysomnography performed which concluded that CSA disappeared. Pathophysiology is still unclear but could involve κ-opioid receptors. Physicians should be aware might affect patients treated Further investigations are required to determine pathophysiology, frequency, associated nalmefene other therapy disorders.